Achieving Robust Drug Product Safety & Efficacy for Reduced Ocular Inflammation

Time: 9:15 am
day: Conference Day One


  • Leveraging lessons from case studies to understand PLGA rods, peptides, degradable depos, polymer-based and matrix binding formulations for ophthalmic drug implants
  • Running effective toxicology studies – examples of getting past the time frame
  • Establishing effective re-dosage to avoid rapid release and reduce inflammatory response
  • Setting up for success – how is manufacturing likely to change from research to development – commercial manufacturing / development process